EIF4E binding peptides
First Claim
Patent Images
1. A method of inhibiting eukaryotic translation initiation factor 4E (eIF4E) by administering of a pharmaceutically effective amount of a modified eukaryotic translation initiation factor 4 gamma 1 (eIF4G1) peptide, wherein the peptide has been modified to stabilize the α
- -helix, wherein the peptide comprises;
(a) the amino acid sequence KKRYDREFLL*FQF (SEQ ID NO;
10);
or(b) the amino acid sequence KKRYDRE*LL*FQF (SEQ ID NO;
2),wherein * represents a non-natural amino acid.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to modified eIF4G1 peptides, uses thereof and pharmaceutical compositions comprising the modified eIF4G1 peptides.
7 Citations
5 Claims
-
1. A method of inhibiting eukaryotic translation initiation factor 4E (eIF4E) by administering of a pharmaceutically effective amount of a modified eukaryotic translation initiation factor 4 gamma 1 (eIF4G1) peptide, wherein the peptide has been modified to stabilize the α
- -helix, wherein the peptide comprises;
(a) the amino acid sequence KKRYDREFLL*FQF (SEQ ID NO;
10);
or(b) the amino acid sequence KKRYDRE*LL*FQF (SEQ ID NO;
2),wherein * represents a non-natural amino acid. - View Dependent Claims (2)
- -helix, wherein the peptide comprises;
-
3. A method for the treatment of autism and cancer, comprising administering a pharmaceutically effective amount of a modified eukaryotic translation initiation factor 4 gamma 1 (eIF4G1) peptide, wherein the peptide has been modified to stabilize the α
- -helix, wherein the peptide comprises;
(a) the amino acid sequence KKRYDREFLL*FQF (SEQ ID NO;
10);
or(b) the amino acid sequence KKRYDRE*LL*FQF (SEQ ID NO;
2),wherein * represents a non-natural amino acid. - View Dependent Claims (4, 5)
- -helix, wherein the peptide comprises;
Specification